In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes

被引：1
|
作者：
Chagla, Zain [1 ]
机构：
[1] St Josephs Healthcare, Hamilton, ON, Canada
来源：
ANNALS OF INTERNAL MEDICINE | 2024年 / 177卷 / 01期
关键词：
D O I：
10.7326/J23-0108
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Source Citation Sommer I, Ledinger D, Thaler K, et al. Outpatient treatment of confirmed COVID-19: a living, rapid evidence review for the American College of Physicians (version 2). Ann Intern Med. 2023;176:1377-1385. 37722115 Clinical Impact Ratings GIM/FP/GP: Infectious Disease: Public Health:
引用
收藏
页码：JC7 / JC7
页数：1
相关论文
共 50 条
  • [21] Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis
    Chen, I-Wen
    Yu, Ting-Sian
    Lin, Chien-Hung
    Hung, Kuo-Chuan
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (06)
  • [22] Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
    Sutanto, Samuel Theodorus
    Sinto, Robert
    Pasaribu, Adeline
    Shakinah, Sharifah
    ACTA MEDICA INDONESIANA, 2022, 54 (04) : 638 - 644
  • [23] Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
    Wei, Yuchen
    Boyer, Christopher
    Jia, Katherine Min
    Lin, Guozhang
    Wang, Huwen
    Li, Conglu
    Hung, Chi Tim
    Jiang, Xiaoting
    Yam, Carrie Ho Kwan
    Chow, Tsz Yu
    Wang, Yawen
    Zhao, Shi
    Guo, Zihao
    Li, Kehang
    Yang, Aimin
    Mok, Chris Ka Pun
    Hui, David S. C.
    Chong, Ka Chun
    Yeoh, Eng Kiong
    EMERGING MICROBES & INFECTIONS, 2025, 14 (01)
  • [24] Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
    Dormuth, Colin R.
    Kim, Jason D.
    Fisher, Anat
    Piszczek, Jolanta
    Kuo, I. Fan
    JAMA NETWORK OPEN, 2023, 6 (10) : E2336678
  • [25] Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
    Reactions Weekly, 2022, 1900 (1) : 4 - 4
  • [26] Nirmatrelvir-ritonavir for outpatients with COVID-19. Case-based approach to assessment and treatment
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : E170 - E174
  • [27] Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non- hospitalised and hospitalised patients with COVID-19: a target trial emulation study
    Wan, Eric Yuk Fai
    Yan, Vincent Ka Chun
    Wong, Zoey Cho Ting
    Chui, Celine Sze Ling
    Lai, Francisco Tsz Tsun
    Li, Xue
    Wong, Carlos King Ho
    Hung, Ivan Fan Ngai
    Lau, Chak Sing
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    ECLINICALMEDICINE, 2023, 64
  • [28] New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
    Atmar, Robert L.
    Finch, Natalie
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (08)
  • [29] Nirmatrelvir-Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
    Zhang, Yi
    Wang, Xinrui
    Huang, Chong
    Yang, Hui
    Jiang, Chunguo
    Yu, Xiaojia
    Hong, Jun
    Zhang, Yi
    Wang, Yushu
    Zhao, Rui
    An, Zhuoling
    Tong, Zhaohui
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 1367 - 1377
  • [30] The Impacts of Nirmatrelvir-Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic
    Gu, Jun
    Han, Zhi-Hua
    Wang, Chang-qian
    Zhang, Jun-feng
    CARDIOVASCULAR DRUGS AND THERAPY, 2024,
12345